Stockscreener 앱 받기
1.24
2.36%
-0.03
시간 외 거래:
1.15
-0.09
-7.26%
Lyell Immunopharma Inc 주식(LYEL)의 최신 뉴스
Lyell Announces Presentation of Initial Clinical Data from - GlobeNewswire
Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting - StockTitan
Vanguard Group Inc's Strategic Reduction in Lyell Immunopharma I - GuruFocus.com
Lyell shares down as BofA double downgrades to Sell - MSN
Lyell Immunopharma (NASDAQ:LYEL) Downgraded to “Underperform” Rating by Bank of America - Defense World
Lyell Immunopharma Completes Acquisition of ImmPACT Bio - The Manila Times
Lyell Immunopharma acquires ImmPACT Bio to boost CAR T-cell therapy - Investing.com India
B of A Securities Downgrades Lyell Immunopharma (LYEL) - MSN
Lyell Immunopharma’s (LYEL) “Neutral” Rating Reiterated at HC Wainwright - Defense World
Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy - Benzinga
Lyell shares down as BofA double downgrades to Sell By Investing.com - Investing.com South Africa
Lyell cut to underperform by BofA, pipeline reorganization cited - MSN
Lyell Immunopharma (NASDAQ:LYEL) Lowered to Underperform Rating by Bank of America - MarketBeat
HC Wainwright Reiterates Neutral Rating for Lyell Immunopharma (NASDAQ:LYEL) - MarketBeat
Lyell Immunopharma’s Acquistion of ImmPACT Bio USA - Global Legal Chronicle
Lyell Will Seek To Improve On Existing CAR-Ts Via Merger With ImmPACT - Citeline News & Insights
Lyell Immunopharma stock hits 52-week low at $1.05 By Investing.com - Investing.com Australia
Lyell goes all in on CAR-T therapies, buys ImmPACT Bio and trims pipeline - Pharmaceutical Technology
Lyell Immunopharma stock hits 52-week low at $1.05 - Investing.com
Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth (NASDAQ:LYEL) - Seeking Alpha
Lyell, in search of a turnaround, to buy cell therapy startup ImmPact - BioPharma Dive
Lyell boosts pipeline with ImmPACT acquisition - Investing.com India
Lyell Immunopharma to Buy ImmPact; Refocuses Pipeline on T-Cell Cancer Treatments - MarketWatch
Lyell Immunopharma to acquire ImmPACT Bio (NASDAQ:LYEL) - Seeking Alpha
Lyell boosts pipeline with ImmPACT acquisition By Investing.com - Investing.com South Africa
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes - GlobeNewswire
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies - StockTitan
Lyell Immunopharma Inc (LYEL) deserves deeper analysis - US Post News
The Manufacturers Life Insurance Company Grows Stock Holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Sees Large Decline in Short Interest - MarketBeat
Lyell Immunopharma Inc (LYEL Stock: A Sea of Opportunity - The InvestChronicle
Lyell Immunopharma stock hits 52-week low at $1.09 - Investing.com
Lyell Immunopharma stock hits 52-week low at $1.09 By Investing.com - Investing.com UK
ProShare Advisors LLC Cuts Stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting - The Manila Times
Lyell Immunopharma Announces the Acceptance Abstracts for - GlobeNewswire
An analyst sees good growth prospects for Lyell Immunopharma Inc (LYEL) - SETE News
XTX Topco Ltd Has $102,000 Stock Holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Lyell Immunopharma Inc (LYEL) Stock: A Year of Declines and Increases - The InvestChronicle
LYEL underperforms with a -0.66 decrease in share price - US Post News
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Shares Sold by Rhumbline Advisers - Defense World
The Significance of Moving Averages in Lyell Immunopharma Inc Inc. (LYEL) Price Performance - The InvestChronicle
2.02%
0.47%
자본화:
|
볼륨(24시간):